MIFH
IMDX

Migdal Insurance & Financial Holdings’s Insight Molecular Diagnostics IMDX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-76
Closed -$3K – 667
2021
Q4 		$3K Sell
76
-46
-38% -$2.65K ﹤0.01% 662
2021
Q3 		$9K Buy
+122
New +$11.2K ﹤0.01% 608

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Migdal Insurance & Financial Holdings's IMDX Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Insight Molecular Diagnostics (IMDX) in Q1 2022, closing a stake of 76 shares — an estimated $3K sold.

Migdal Insurance & Financial Holdings first reported a position in IMDX in Q3 2021 and held it in 2 quarters. The position peaked at $9K in Q3 2021. 86 funds tracked by Wall St. Rank hold IMDX as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Insight Molecular Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 76 Insight Molecular Diagnostics shares in Q1 2022, an estimated $3K.
  • Migdal Insurance & Financial Holdings first reported a position in Insight Molecular Diagnostics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Insight Molecular Diagnostics position peaked at $9K in Q3 2021.
  • 86 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.